Fusen Pharmaceutical Company Limited
福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

VOLUNTARY ANNOUNCEMENT
"AGOMELATINE TABLETS" APPROVED FOR MARKETING

The board (the "**Board**") of directors (the "**Directors**") of Fusen Pharmaceutical Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that "Agomelatine Tablets" (阿戈美拉汀片, trademark: 悦舒樂) developed by Henan Fusen Pharmaceutical Company Limited, a wholly-owned subsidiary of the Company, has obtained the approval for marketing from the National Medical Products Administration of the PRC (國家藥品監督管理局) for the treatment of depression in adults.

Depression is a common mental disorder affecting over 300 million patients worldwide. Conventional antidepressants exert their effects primarily by regulating monoamine neurotransmitters; however, they are often limited by delayed onset of action and display notable side effects. "Agomelatine Tablets" is a novel antidepressant with a unique mechanism that extends beyond the traditional monoamine transmitter system. It acts as an agonist at melatonin (MT1 and MT2) receptors and an antagonist at 5-hydroxytryptamine (5-HT) receptors, thereby exhibiting pharmacological properties of sleep-regulation and as an antidepressant.

Agomelatine exerts its antidepressant effect by antagonising postsynaptic 5-HT2C receptors, which leads to increased dopamine and norepinephrine release in the prefrontal cortex. At the same time, it activates melatonin MT1 and MT2 receptors, resynchronising disrupted circadian rhythms and shortening sleep latency, while prolonging total sleep time and improving sleep quality. Moreover, Agomelatine has been shown to effectively alleviate accompanying symptoms such as depressed mood, attention deficits, and memory impairment by regulating central neural circuits involved in emotion and cognition, thus contributing to the full recovery of patients' psychosocial functioning.

"Agomelatine Tablets" is a Class B drug under the National Reimbursement Drug List. It is recommended as a first-line antidepressant by authoritative guidelines both domestically and internationally, including the *Chinese Guidelines for the Prevention and Treatment of Depressive Disorders*, the *Chinese Guidelines for the Diagnosis and Treatment of Insomnia Disorder in Adults*, and the *Canadian Network for Mood and Anxiety Treatments/ International Society for Bipolar Disorders (CANMAT/ISBD) Treatment Guidelines for Bipolar Disorder*. According to data from Menet, the sales revenue of Agomelatine Tablets across the three major terminals and six major markets in the PRC exceeded RMB700 million in aggregate in 2025.

"Agomelatine Tablets" is another important product of the Group, which further enriches the Company's antidepressant product pipeline. The marketing of this product will provide more therapeutic options for millions of patients diagnosed with depression.

By order of the Board
Fusen Pharmaceutical Company Limited
Mr. Cao Zhiming
Chairman and Executive Director

Hong Kong, 8 June 2026

As at the date of this announcement, the Board of the Company comprises Mr. Cao Zhiming (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng and Ms. Meng Qingfen as executive Directors, and Mr. Lee Kwok Tung Louis, Dr. To Kit Wa and Mr. Yu Ho Ming as independent non-executive Directors.